Shots:

• Fusion to receive up front- as well as development milestones and other payments. The companies will jointly discover- develop- and have an option to co-commercialize novel TATs in the US while AstraZeneca will lead commercialization in the ROW with equal profit & loss sharing globally
• The collaboration leverages Fusion’s TAT platform and expertise in radiopharmaceuticals with AstraZeneca's leading portfolio of Abs and cancer therapies- including DDRis
• Additionally- the companies will exclusively explore certain specified combination strategies between TATs (including Fusion's FPI-1434) and AstraZeneca’s therapies for the treatment of multiple cancers. Both companies will retain full rights to their respective assets

  Ref: Fusion Pharmaceuticals | Image: The Scientist Magazine